Phase 1 clinical trial to assess the pharmacokinetics, safety and tolerance of a zanamivir transdermal system in healthy subjects
Active Cooperative Agreement Awarded Last action
- Award ID
- U44AI184201
- Recipient
-
Tsrl, Inc. UEI TP74UMNGJDJ1
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,291,914
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 55% complete
- Originally
- Place of performance
- Ann Arbor, MI 48108, USA
Award details come from USAspending.gov.
Description
- Abstract
- Yearly influenza epidemics strike millions of people, resulting in up to 500,000 deaths. Fatalities caused by most seasonal influenza viruses is
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $999,298 | |
| Amendment | -$65 | |
| Amendment | -$65 | |
| Original award | $292,746 |
Quick answers
Who received award U44AI184201?
U44AI184201 was awarded to Tsrl, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 10, 2024.
How much is award U44AI184201 worth?
$1,291,914 has been obligated on U44AI184201.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award